Dabrafenib plus trametinib show activity in certain patients with colorectal cancer

Share this content:

the ONA take:

The combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant metastatic colorectal cancer (mCRC), a new study published online ahead of print in the Journal of Clinical Oncology has shown.

For the study, researchers enrolled 43 patients with BRAF V600-mutant metastatic colorectal cancer and assigned them to receive dabrafenib 150 mg twice daily plus trametinib 2 mg daily.

Results showed that 12% of patients achieved a partial response or better, including one complete response. Furthermore, 56% of patients achieved stable disease as best confirmed response.

Dabrafenib in combination with trametinib is already indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations.

The most common adverse events associated with combination dabrafenib-trametinib therapy are pyrexia, chills, fatigue, rash, nausea, vomiting, diarrhea, abdominal pain, headache, arthralgia, night sweats, decreased appetite, constipation, and myalgia.

The combination is also being studied for the treatment of a variety of other solid tumors, including ovarian cancer, thyroid cancer, and non-small cell lung cancer.

New guidelines address long-term needs of colorectal cancer survivors
Combination of dabrafenib plus trametinib has activity in a subset of patients with BRAF V600-mutant metastatic colorectal cancer.
Ryan B. Corcoran, Eunice L. Kwak, and David P. Ryan, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Chloe E. Atreya, Adil Daud, and Alan P. Venook, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco; Omid Hamid, Angeles Clinic and Research Institute, Los Angeles, CA; Gerald S.
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs